reference/4420539

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/4420539

Outgoing Links

Predicate	Object
contentType	Clinical Trial\|Clinical Trial, Phase I\|Clinical Trial, Phase II\|Comparative Study\|Controlled Clinical Trial\|Journal Article\|Multicenter Study\|Research Support, Non-U.S. Gov't
endingPage	565
issn	1592-8721 0390-6078
issueIdentifier	4
pageRange	560-565
publicationName	Haematologica
startingPage	560
bibliographicCitation	Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M, Garcia-Sanchez P, Lahuerta JJ, de la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, Alegre A, de Arriba F, Oriol A, Carrera D, García-Laraña J, García-Sanz R, Bladé J, Prósper F, Mateo G, Esseltine DL, van de Velde H, San Miguel JF. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica. 2008 Apr;93(4):560–5. doi: 10.3324/haematol.12106. PMID: 18322252.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f89da2305c176258e58c1eb4b1b8f3d7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f7bc0a3e6cc7700cb7cee249effbc44d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_16ad893244b7513b307d03934dece10e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_517759482f00b63919a276d5d82da520 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4eee2e158acb7e72025cc3fc00fc1972 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1881098bfd52126659c569aeac0a80ff http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7648114e75b1c99728b9ea663e87acab http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_89bd11ee2a178ac0be309c3361d19146 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7a07fb1f83b3d9b46171b554dbfc3d90 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5e77fffe44f409433302c436b00f8d71 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0f97b622bf97089c2bb290e9f90e1c90 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ff29c7703be9e09e90c7031a2c8f059c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5cc3ea4e8becacb4d9935e35588b64f7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_790809b04e3367e32f763ed8647e6130 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_280471a9ef7470b024beef911ef6b0c3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-2423-822X http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a98aaf9bdf94ef8c2c128a2fb50f2059 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d3181743e1ca401b973d044c6703e90b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_71c4309babea2bde322998e8ae184e48 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_48fa470cda35aae7ca976202cfb9fa4d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_db459e44a3f0d734afaa24d613478a78 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a073978b79b0ef383f41eca1870d403e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5590c32f6da5c21048545a2fe6b93280 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cfc09a20fb0c441f1849ca15513c5ba3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_93ae6317e39df3507d5c87bdce65e8eb http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_779b66b38fa3b4d4a7ca566bada010c9
date	2008-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/18322252 https://doi.org/10.3324/haematol.12106
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/3942 https://portal.issn.org/resource/ISSN/0390-6078 https://portal.issn.org/resource/ISSN/1592-8721
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression
discusses	http://id.nlm.nih.gov/mesh/M0018225 http://id.nlm.nih.gov/mesh/M0017465 http://id.nlm.nih.gov/mesh/M0350110 http://id.nlm.nih.gov/mesh/M0022149 http://id.nlm.nih.gov/mesh/M0002834 http://id.nlm.nih.gov/mesh/M0013330
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D009101Q000188 http://id.nlm.nih.gov/mesh/D000971Q000627
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D018572 http://id.nlm.nih.gov/mesh/D006402Q000139 http://id.nlm.nih.gov/mesh/D014408Q000032 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D005500 http://id.nlm.nih.gov/mesh/D011241Q000009 http://id.nlm.nih.gov/mesh/D011241Q000008 http://id.nlm.nih.gov/mesh/D011719Q000009 http://id.nlm.nih.gov/mesh/D018450 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D011719Q000008 http://id.nlm.nih.gov/mesh/D016019 http://id.nlm.nih.gov/mesh/D008558Q000009 http://id.nlm.nih.gov/mesh/D005767Q000139 http://id.nlm.nih.gov/mesh/D017567 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D008558Q000008 http://id.nlm.nih.gov/mesh/D009101Q000235 http://id.nlm.nih.gov/mesh/D001897Q000009 http://id.nlm.nih.gov/mesh/D001897Q000008 http://id.nlm.nih.gov/mesh/D009101Q000401 http://id.nlm.nih.gov/mesh/D000369 http://id.nlm.nih.gov/mesh/D011379 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D000069286 http://id.nlm.nih.gov/mesh/D000971Q000009
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_c37c4e80515b927da0969aacdb9547a9 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID460612 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7277 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID387447 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_73717aafac1e7701dab0fa02b8936926 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8530 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5865

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID243055978 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129717275 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128334455

Total number of triples: 89.